US45784P1012 - Common Stock
INSULET CORP
NASDAQ:PODD (5/7/2024, 11:28:00 AM)
182.875
+6.47 (+3.67%)
Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts and currently employs 2,600 full-time employees. The company went IPO on 2007-05-15. The Omnipod System includes the Omnipod Insulin Management System (Classic Omnipod), the Omnipod DASH Insulin Management System (Omnipod DASH), and the Omnipod 5 Automated Insulin Delivery System (Omnipod 5). The Omnipod System features a small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod) that the user fills with insulin and wears directly on the body for up to three days at a time, which delivers personalized doses of insulin, and the Personal Diabetes Manager (PDM) or Controller, a wireless, handheld device that programs the Pod with the user's personalized insulin-delivery instructions and wirelessly monitors the Pod's operation. The firm sells Pods to Amgen Inc. (Amgen) for use in the Neulasta Onpro kit, a delivery system for Amgen's Neulasta.
INSULET CORP
100 Nagog Park
Acton MASSACHUSETTS 01720
P: 19786007000
CEO: Shacey Petrovic
Employees: 2600
Website: https://www.omnipod.com
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Tuesday.
Is INSULET CORP (NASDAQ:PODD) on the Verge of a Major Breakout as a Strong Growth Stock?
Leverage Oprah's shift to prescription weight solutions with Weight-Loss ETFs, targeting companies leading in obesity treatment.
These 7 stable stocks also offer 50% returns according to analysts according to analysts tasked with following their respective industries.
Here you can normally see the latest stock twits on PODD, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: